Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehmet Altan

Showing results (121-130 of 154) with videos related to

Pageof 16
Sort By:
Scientific Reports|August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical TrialTito R Mendoza, David S Hong, Christine B Peterson, et al.
Frontiers in Oncology|August 28, 2023
Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operationsNathaniel Deboever, Nicolas Zhou, Daniel J McGrail, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 4, 2024
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinomaKelsey L Corrigan, Ting Xu, Yuki Sasaki, et al.
Frontiers in Immunology|October 16, 2023
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of conceptMuhammad Aminu, Naval Daver, Myrna C B Godoy, et al.
Breast Cancer Research : BCR|November 5, 2025
Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort studyMaria Azhar, Felipe Soto, Amber Su, et al.
JTO Clinical and Research Reports|August 31, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLCKaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, et al.
American Journal of Respiratory Cell and Molecular Biology|October 10, 2025
Macrophage CCL18 Promotes Lung Inflammation in Checkpoint Inhibitor PneumonitisMohammad I Ghanbar, Andres Villabona-Rueda, Nicolas Philip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2025
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case ReportBingnan Zhang, Komal B Shah, Mitchell Parma, et al.
Nature Communications|September 26, 2025
Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samplesNejla Ozirmak Lermi, Max Molina Ayala, Sharia Hernandez, et al.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
CT-Based Deep Foundation Model for Predicting Immune Checkpoint Inhibitor-Induced Pneumonitis Risk in Lung CancerAmgad Muneer, Eman Showkatian, Yuliya Kitsel, et al.
Pageof 16

Showing results (121-130 of 154) with videos related to

Sort By:
Pageof 16
Scientific Reports|August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical TrialTito R Mendoza, David S Hong, Christine B Peterson, et al.
Frontiers in Oncology|August 28, 2023
Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operationsNathaniel Deboever, Nicolas Zhou, Daniel J McGrail, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 4, 2024
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinomaKelsey L Corrigan, Ting Xu, Yuki Sasaki, et al.
Frontiers in Immunology|October 16, 2023
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of conceptMuhammad Aminu, Naval Daver, Myrna C B Godoy, et al.
Breast Cancer Research : BCR|November 5, 2025
Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort studyMaria Azhar, Felipe Soto, Amber Su, et al.
JTO Clinical and Research Reports|August 31, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLCKaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, et al.
American Journal of Respiratory Cell and Molecular Biology|October 10, 2025
Macrophage CCL18 Promotes Lung Inflammation in Checkpoint Inhibitor PneumonitisMohammad I Ghanbar, Andres Villabona-Rueda, Nicolas Philip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2025
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case ReportBingnan Zhang, Komal B Shah, Mitchell Parma, et al.
Nature Communications|September 26, 2025
Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samplesNejla Ozirmak Lermi, Max Molina Ayala, Sharia Hernandez, et al.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
CT-Based Deep Foundation Model for Predicting Immune Checkpoint Inhibitor-Induced Pneumonitis Risk in Lung CancerAmgad Muneer, Eman Showkatian, Yuliya Kitsel, et al.
Pageof 16